Who is sponsoring NCT01342380?

NCT01342380 is sponsored by University Hospitals Cleveland Medical Center.

What condition does NCT01342380 study?

NCT01342380 studies Bipolar Disorder, Major Depressive Disorder.

What is the status of NCT01342380?

NCT01342380 is currently COMPLETED.

Last reviewed 2023-07-14 · How we verify

Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders

NCT01342380 COMPLETED

Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.

Details

Lead sponsor	University Hospitals Cleveland Medical Center
Status	COMPLETED
Enrolment	42
Start date	2011-02
Completion	2015-05

Conditions

Bipolar Disorder
Major Depressive Disorder

Primary outcomes

Genetic markers associated with treatment response — Up to 1.5 years
Genetic markers in PPARG, 5-HT2A, CYP3A4 and CYP2C8 genes known to be related in the pharmacodynamics and pharmacokinetics of pioglitazone or quetiapine XR will be associated with treatment response.

Countries

United States